BioLife Solutions (NASDAQ:BLFS) Stock Price Down 2.5%

BioLife Solutions, Inc. (NASDAQ:BLFS)’s stock price fell 2.5% on Wednesday . The company traded as low as $19.72 and last traded at $19.72. 59,668 shares were traded during trading, a decline of 85% from the average session volume of 399,443 shares. The stock had previously closed at $20.23.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BLFS. Benchmark upgraded shares of BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Monday, May 13th. StockNews.com upgraded shares of BioLife Solutions to a “sell” rating in a research report on Friday, May 10th. Finally, Jefferies Financial Group began coverage on shares of BioLife Solutions in a research report on Thursday, April 4th. They set a “buy” rating and a $22.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to MarketBeat, BioLife Solutions presently has an average rating of “Moderate Buy” and an average target price of $23.67.

BioLife Solutions Stock Down 1.0 %

The stock’s 50-day moving average price is $20.39 and its 200 day moving average price is $18.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Thursday, May 9th. The medical equipment provider reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.06. BioLife Solutions had a negative net margin of 45.84% and a negative return on equity of 12.89%. The business had revenue of $31.73 million during the quarter, compared to analysts’ expectations of $29.30 million. During the same period in the prior year, the business earned ($0.27) earnings per share. As a group, equities research analysts predict that BioLife Solutions, Inc. will post -0.44 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CMO Todd Berard sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $20.18, for a total transaction of $201,800.00. Following the completion of the sale, the chief marketing officer now directly owns 108,894 shares in the company, valued at $2,197,480.92. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 24,845 shares of company stock worth $447,644. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its stake in BioLife Solutions by 167.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 1,020 shares during the period. GAMMA Investing LLC purchased a new position in BioLife Solutions during the fourth quarter worth about $41,000. Register Financial Advisors LLC purchased a new position in BioLife Solutions during the first quarter worth about $96,000. State Board of Administration of Florida Retirement System purchased a new position in BioLife Solutions during the first quarter worth about $229,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in BioLife Solutions by 10.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock worth $281,000 after buying an additional 1,374 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.